Eagle Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was $404.8 Mil.
Warning Sign:
If a company builds assets at 12.2% a year, faster than its revenue growth rate of 6.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Eagle Pharmaceuticals's average Total Assets Growth Rate was 12.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 34.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 12.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 52.40% per year.
During the past 11 years, Eagle Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 176.40%. The lowest was -3.60%. And the median was 43.15%.
Eagle Pharmaceuticals Total Assets Historical Data
The historical data trend for Eagle Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Eagle Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eagle Pharmaceuticals (NAS:EGRX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Eagle Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Eagle Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EGRX has been successfully added to your 